| Autor: |
Patricia V. Gaya, Juliana R. Santos, Paulo R. X. Tomaz, Tania M. O. Abe, Miguel Nassif Jr, Larissa G. Galas, Bianca B. Bellini, Iana R. Moraes, Paulo C. Lima Santos, Paulo C. R. P. Correa, Jaqueline R. Scholz |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Tobacco Induced Diseases, Vol 22, Iss April, Pp 1-12 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1617-9625 |
| DOI: |
10.18332/tid/186072 |
| Popis: |
Introduction Smoking cessation is the best strategy for reducing tobacco-related morbimortality. The goal of this randomized controlled trial was to test whether using the genetically favorable markers to choose a smoking cessation drug treatment (precision medicine) was superior to using the most effective drug (varenicline) in terms of abstinence rates. Additionally, combination therapy was tested when monotherapy failed. Methods This partially blind, single-center study randomized (1:1) 361 participants into two major groups. In the genetic group (n=184), CYP2B6 rs2279343 (genotype AA) participants started treatment with bupropion, and CHRNA4 rs1044396 (genotype CT or TT) participants started treatment with varenicline; when genetic favorable to both, participants started treatment with bupropion, and when favorable to neither, on both drugs. In the control group (n=177), participants started treatment with varenicline, regardless of genetic markers. Drug treatment lasted 12 weeks. Efficacy endpoints were abstinence rates at Weeks 4, and Weeks 8–12, biochemically validated by carbon monoxide in exhaled air. Participants who did not achieve complete abstinence at Week 4, regardless of group, were given the choice to receive combination therapy. Results Abstinence rates were 42.9% (95% CI: 36–64) in the control group versus 30.4% (95% CI: 23–37) in the genetic group at Week 4 (p=0.01); and 74% (95% CI: 67–80) versus 52% (95% CI: 49–64) at Week 12 (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
